The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians.

Détails

Ressource 1Télécharger: 20104374.pdf (94.01 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_30FEF31AFC68
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians.
Périodique
Swiss medical weekly
Auteur(s)
Bihl F., Alaei M., Negro F.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
20/03/2010
Peer-reviewed
Oui
Volume
140
Numéro
11-12
Pages
154-159
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Since the arrival of several new antivirals and due to the growing molecular and clinical knowledge of hepatitis B virus (HBV) infection, therapy of hepatitis B has become complex. Clinical guidelines aim at streamlining medical attitudes: in this respect, the European Association for the Study of the Liver (EASL) recently issued clinical practice guidelines for the management of chronic hepatitis B. Guidelines made by international experts need however to be adapted to local health care systems. Here, we summarise the EASL guidelines with some minor modifications in order to be compatible with the particular Swiss situation, while discussing in more detail some aspects. Chronic hepatitis B is a complex disease with several phases where host and viral factors interact: the features of this continuous interplay need to be evaluated when choosing the most appropriate treatment. The EASL guidelines recommend, as first-line agents, using the most potent antivirals available with the optimal resistance profile, in order to abate HBV DNA as rapidly and as sustainably as possible. Once therapy has been started, the infection evolves and resistant viral strains may emerge. Rescue therapy needs to be started early with more potent agents lacking cross-resistance.

Mots-clé
Antiviral Agents/therapeutic use, Comorbidity, Drug Resistance, Female, HIV Infections, Health Personnel, Hepatitis B virus/drug effects, Hepatitis B virus/genetics, Hepatitis B, Chronic/drug therapy, Hepatitis B, Chronic/physiopathology, Hepatitis B, Chronic/virology, Humans, Immunocompromised Host, Liver Cirrhosis/prevention & control, Male, Practice Guidelines as Topic, Practice Patterns, Physicians', Pregnancy, Switzerland
Pubmed
Web of science
Création de la notice
14/02/2011 8:47
Dernière modification de la notice
20/08/2019 13:15
Données d'usage